AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
March 28 2024 - 8:05AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”) today announced that
Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech,
will present at the MedInvest Biotech & Pharma Investor
Conference being held in New York, N.Y., on Wednesday, April 3,
2024, at 1:35 PM ET.
In addition to the presentation, management will
be available to participate in one-on-one meetings with qualified
members of the investor community who are registered to attend the
conference. For more information about the event, please visit the
conference website.
A live webcast of the presentation will be
available on the Events page of Investors section of the Company’s
website (www.aimimmuno.com).
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.For more information,
please visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2023 to Apr 2024